Small molecule antagonists of chemokine receptors as emerging anti-HIV agents
- 1 August 2001
- journal article
- Published by Informa Healthcare in Expert Opinion on Therapeutic Patents
- Vol. 11 (8) , 1245-1252
- https://doi.org/10.1517/13543776.11.8.1245
Abstract
HIV entry into the cell involves the presence of at least two chemokine coreceptors, the CCR5 and CXCR4 receptors. Much research by the major drug companies has ultimately been directed to the deve...Keywords
This publication has 21 references indexed in Scilit:
- Human immunodeficiency virus type-1 and chemokines: beyond competition for common cellular receptorsCytokine & Growth Factor Reviews, 2001
- Mechanisms of Viral Membrane Fusion and Its InhibitionAnnual Review of Biochemistry, 2001
- Human Immunodeficiency Virus Type 1 Entry Inhibitors PRO 542 and T‐20 Are Potently Synergistic in Blocking Virus‐Cell and Cell‐Cell FusionThe Journal of Infectious Diseases, 2001
- From receptor recognition mechanisms to bioinspired mimetic antagonists in HIV-1/cell dockingJournal of Chromatography B: Biomedical Sciences and Applications, 2001
- Protein Design of an HIV-1 Entry InhibitorScience, 2001
- N- and C-domains of HIV-1 gp41: mutation, structure and functionsImmunology Letters, 2001
- Inhibitors of HIV cellular fusionExpert Opinion on Therapeutic Patents, 2000
- Current Evidence and Future Directions for Targeting HIV EntryJAMA, 2000
- HIV-1 entry – an expanding portal for drug discoveryDrug Discovery Today, 2000
- Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibodyNature, 1998